[The biological fate of 4-butyl-4-(beta-carboxypropionyloxymethyl)-1,2-diphenyl-3,5-pyrazolidinedione(suxibuzone), antiinflammatory drug. I. Plasma levels and urinary excretion after oral administration of suxibuzone (author's transl)]

[Article in Japanese]

Comparative Study

[Article in Japanese]

T Shindo et al. Yakugaku Zasshi. 1979 Dec.

. 1979 Dec;99(12):1186-200.

doi: 10.1248/yakushi1947.99.12_1186.

No abstract available

Similar articles

[The biological fate of 4-butyl-4-(beta-carboxypropionyloxymethyl)-1,2-diphenyl-3,5-pyrazolidinedione (suxibuzone), antiinflammatory drug. II. The biological fate of suxibuzone (SB) after daily oral administration (author's transl)].
Taira K, Yasuda Y, Shindo T, Mitani N, Akazawa A. Taira K, et al. Yakugaku Zasshi. 1980 Mar;100(3):272-9. doi: 10.1248/yakushi1947.100.3_272. Yakugaku Zasshi. 1980. PMID: 7381687 Japanese. No abstract available.
Comparison of the absorption, excretion, and metabolism of suxibuzone and phenylbutazone in humans.
Yasuda Y, Shindo T, Mitani N, Ishida N, Oono F, Kageyama T. Yasuda Y, et al. J Pharm Sci. 1982 May;71(5):565-72. doi: 10.1002/jps.2600710521. J Pharm Sci. 1982. PMID: 7097505
The disposition of suxibuzone in the horse.
Delbeke FT, Vynckier L, Debackere M. Delbeke FT, et al. J Vet Pharmacol Ther. 1993 Sep;16(3):283-90. doi: 10.1111/j.1365-2885.1993.tb00175.x. J Vet Pharmacol Ther. 1993. PMID: 8230399
[Biological availability and solubility of phenylbutazone].
Krówczyński L, Jachowicz R, Wajdowicz A. Krówczyński L, et al. Folia Med Cracov. 1979;21(1):141-7. Folia Med Cracov. 1979. PMID: 396188 Review. Polish. No abstract available.
[The use of analgesic and antiphlogistic agents in small animals (author's transl)].
Meutstege FJ. Meutstege FJ. Tijdschr Diergeneeskd. 1975 May 1;100(9):509-15. Tijdschr Diergeneeskd. 1975. PMID: 241131 Review. Dutch.